
|Videos|April 1, 2022
Dr. Tagawa on the growing role of radiopharmaceuticals in prostate cancer
Author(s)Urology Times staff
“What I'm quite hopeful for are PSMA-targeted alpha emitters,” says Scott T. Tagawa, MD, MS, FACP.
Advertisement
In this video, Scott T. Tagawa, MD, MS, FACP, discusses ongoing and upcoming innovation in the radiopharmaceutical space for treatment of prostate cancer, as well as considerations for physicians who are administering these therapies. Tagawa is an associate professor of clinical medicine and clinical urology and medical director of the Genitourinary Oncology Research Program at Weill Cornell Medicine in New York City. He is also an assistant attending physician on the Cornell campus at New York-Presbyterian Hospital.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Study to assess adaptive-dosed 177Lu-DOTA-HYNIC-panPSMA in mHSPC
2
Practical tips for AE management with the gemcitabine intravesical system
3
Team-based AE protocols improve consistency with the gemcitabine intravesical therapy system
4
Residual stone volume outperforms stone-free rate as risk marker
5












